Biohaven showcases broad innovative portfolio and pipeline updates across multiple therapeutic areas including immunology, neuroscience, metabolic disorders and oncology at annual investor r&d day

Reports new positive interim data from the ongoing phase 1 study of bhv-1300, biohaven's lead investigational drug from its molecular degrader of extracellular proteins (mode™) platform bhv-1300 demonstrates dose-dependent and rapid igg reductions within hours of administration no saes, no severe aes,  most aes were mild, deemed unrelated to study drug and resolved spontaneously no clinically significant changes in lfts across any dose cohorts to date highlights advances from novel ion channel program targeting kv7 activation and trpm3 antagonism across multiple neurological, pain and neuropsychiatric disease indications recently initiated a total of 5 pivotal clinical trials with selective kv7 activator, bhv-7000, targeting focal epilepsy, idiopathic generalized epilepsy, bipolar disorder and major depressive disorder released positive phase 1 data with trpm3 antagonist bhv-2100 showing drug concentrations above ec90 target and well-tolerated profile across all doses in sad/mad study; advancing phase 2 study in migraine anticipates myostatin program topline data for phase 3 spinal muscular atrophy (sma) study in 2h2024 reports new preclinical data highlighting potential for taldefgrobep alfa as monotherapy and in combination with glp-1 agonists for weight loss: taldefgrobep alfa in combination with glp-1 in the diet-induced obesity preclinical model showed greater reductions in body weight and fat mass, and a larger increase in lean muscle mass, compared to glp-1 alone taldefgrobep alfa demonstrated direct effects on fat reduction as measured by changes in adipocytes independent of increasing muscle mass releases positive phase 1 data with bhv-8000, a brain-penetrant tyk2/jak1 inhibitor, showing preliminary safety and achievement of target concentrations with reductions in inflammatory biomarkers in sad/mad study key updates for bhv-8000 include favorable regulatory feedback enabling initiation of registrational programs for the prevention of aria associated with amyloid lowering drugs and parkinson's disease as announced in an earlier press release today, first patient dosed with biohaven's novel trop-2 antibody drug conjugate (adc), bhv-1510, in phase 1/2 trial, as monotherapy and initiating combination with regeneron's anti-pdl1 libtayo®(cemiplimab-rwlc), in advanced or metastatic epithelial tumors new haven, conn. , may 29, 2024 /prnewswire/ -- biohaven ltd.
BHVN Ratings Summary
BHVN Quant Ranking